NeoGenomics Buys Clarient from GE Healthcare
Represented GE Healthcare in its sale of Clarient, Inc. to NeoGenomics, Inc. for cash, $110 million in preferred stock and 15 million shares of NeoGenomics common stock.
GE Healthcare is a provider of transformational medical technologies and services. Clarient, Inc. was a provider of anatomic pathology and molecular testing services.*
*prior firm experience